Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks.

about

Common GI Drug Interactions in the Elderly.Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace.Functional evaluation of synthetic flavonoids and chalcones for potential antiviral and anticancer properties.

P2860

Q38230328-B91735E8-477E-4E53-9047-9F086BE4F0B5 Q38515906-CBA32635-97A6-4209-AF0E-40E55140AE5C Q40228338-4CC6381C-449B-4A18-8891-932CA795B1D5

P2860

Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks.

Item

http://www.wikidata.org/entity/Q38205737

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks.

@en

type

Item

label

Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks.

@en

prefLabel

Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks.

@en

P1476

Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks.

@en

P2093

George M Abraham

http://www.w3.org/2001/XMLSchema#string

Linda M Spooner

http://www.w3.org/2001/XMLSchema#string

P2860

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

Viral Determinants of Resistance to Treatment in Patients with Hepatitis C

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

Diagnosis, management, and treatment of hepatitis C: an update

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

Sofosbuvir for previously untreated chronic hepatitis C infection

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C.

RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.

P304

411-415

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIU265

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261761308

http://www.w3.org/2001/XMLSchema#string

P698

24748524

http://www.w3.org/2001/XMLSchema#string

P921

sofosbuvir

Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks.

about

P2860

P2860

Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921